117765-67-0

Basic information

• Product Name: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate
• Synonyms: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate;2-[(methylphenylamino)sulfonyl]Acetic acid methyl ester
• CAS NO: 117765-67-0
• Molecular Formula: C₁₀H₁₃NO₄S
• Molecular Weight: 243.27952
• Mol File: 117765-67-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate(117765-67-0)
• EPA Substance Registry System: Methyl 2-(N-Methyl-N-phenylsulfaMoyl)acetate(117765-67-0)

Safety Data

• Hazardous Substances Data: 117765-67-0(Hazardous Substances Data)

Upstream product

• 56146-83-9 chlorosulfonyl-acetic acid methyl ester 
• 62-53-3 aniline 
• 100-61-8 N-methylaniline 

Downstream Products

• 957070-16-5 tert-butyl 4-(2-methoxy-1-{[methyl(phenyl)amino]sulfonyl}-2-oxoethyl)benzoate 
• 1136056-58-0 methyl 1-(N-methyl-N-phenylaminosulfonyl)cyclopropanecarboxylate 
• 1001915-85-0 methyl (3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]-pyridin-7-yl)[methyl(phenyl)sulfamoyl]acetate 
• 1001915-86-1 1-(3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-methyl-N-phenylmethanesulfonamide 
• 1001915-87-2 N-methyl-1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo-[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-phenylmethanesulfonamide 

Relevant articles and documents

INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS

Compounds of general formula (I), wherein R1, R11, Y, R2, n and A are as defined herein are useful as inhibitors or metallo-β-lactamase (MBL) enzymes and can be used for reducing or removing antibiotic resistance in bacteria.

Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5] cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met

This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under investigation as a treatment for cancer. The design of 11r was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access 11r and analogues. We provide a rationale for the observed selectivity based on X-ray crystallographic evidence and discuss selectivity trends with additional examples. Importantly, 11r provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase conformation.

Tyrosine kinase inhibitors

The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

Synthesis of sultams by cycloalkylation of (alkoxycarbonylmethane) sulfonanilides

(Methoxycarbonylmethane)sulfonanilides are alkylated by α, ω-dihaloalkanes in K2CO3-DMF with the formation of sultams. A high sensitivity has been detected for the reaction rate on the electronic effect of substituents in the aromatic nucleus, although substituents in the ortho position do not obstruct the reaction and in the case of 2,6-disubstituted derivatives the reaction rate and sultam yield were maximal. Tertiary sulfonamides form derivatives of 1-sulfamoylcyclopropanecarboxylic acid under these conditions.

A new strategy for the synthesis of benzylic sulfonamides: Palladium-catalyzed arylation and sulfonamide metathesis

(Chemical Equation Presented) An efficient two-step strategy has been developed to access diversely functionalized benzylic sulfonamides. Execution of this strategy required the development of two reaction methods: the palladium-catalyzed cross-coupling of aryl halides with CH-acidic methanesulfonamides and a metathesis reaction between the resulting α-arylated sulfonamides and diverse amines. The broad scope of the cross-coupling process combined with a versatile sulfonamide metathesis constitutes an efficient strategy for the synthesis of various benzylic sulfonamides.

Synthese, complexation et mecanisme d'hydrolyse de sulfamoylacetates d'alkyle, inhibiteurs de l'alcool coniferylique deshydrogenase

Alkyl sulfamoylacetates and their derivatives, inhibitors of coniferylalcohol deshydrogenase (CADH), were prepared with 40-80percent yield either by oxidation of the corresponding alkyl sulfinamoylacetates or by reaction of functionnalised sulfonyl chlorides with amines.The kinetics of hydrolysis of methyl N-phenyl sulfamoylacetate 7 leads us to propose a BAC2 mechanism of slow hydroxide ion attack at the carbonyl carbon atom.It is different from that proposed for the basic hydrolysis of the alkylsulfinamoylacetates.Sulfamoylesters do not complex ZnBr2 in CHCl3 medium at the contrary of the sulfinamoylesters.The sites and the complexation constants have been found by 1H NMR, using shift reagent .The reaction of ZnBr2/THF with the tert-butyl esters of the titled compounds leads to the formation of the Zn2+ salt of the acid.These results have been correlated with the differences of biologic activity of these compounds during the inactivation of CADH.